Telomir Pharmaceuticals, Inc.
TELO
$4.68
-$0.35-6.96%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.64M | 5.38M | 879.70K | 1.11M | 874.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.91M | 6.01M | 1.47M | 1.92M | 1.08M |
| Operating Income | -2.91M | -6.01M | -1.47M | -1.92M | -1.08M |
| Income Before Tax | -2.90M | -5.99M | -1.45M | -6.25M | -9.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.90M | -5.99M | -1.45M | -6.25M | -9.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.90M | -5.99M | -1.45M | -6.25M | -9.33M |
| EBIT | -2.91M | -6.01M | -1.47M | -1.92M | -1.08M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.10 | -0.20 | -0.05 | -0.23 | -0.34 |
| Normalized Basic EPS | -0.06 | -0.13 | -0.03 | -0.14 | -0.04 |
| EPS Diluted | -0.10 | -0.20 | -0.05 | -0.23 | -0.34 |
| Normalized Diluted EPS | -0.06 | -0.13 | -0.03 | -0.14 | -0.04 |
| Average Basic Shares Outstanding | 29.66M | 29.61M | 29.61M | 27.77M | 27.10M |
| Average Diluted Shares Outstanding | 29.66M | 29.61M | 29.61M | 27.77M | 27.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
